9813444

Gregoriou O

1998

Evaluation of ovarian cysts following GnRH-a treatment in patients with polycystic ovarian syndrome.

9814480

Willis DS

1998

Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation.

9823701

Aquino Carlos P

1998

[Insulin resistance in polycystic ovary syndrome].

9828903

Buckler HM

1998

The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women.

9828911

Garcia-Rudaz C

1998

Peripheral catecholamine alterations in adolescents with polycystic ovary syndrome.

9830746

Devoto E

1998

[Has oligomenorrhea a pathological meaning? The importance of this symptom in internal medicine].

9831312

Strowitzki T

1998

Low-dose FSH stimulation in polycystic ovary syndrome: comparison of 3 FSH-preparations.

9843997

Legro RS

1998

Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

9849709

G?ven M

1998

Glucocorticoid receptors on mononuclear leukocytes in polycystic ovary syndrome.

9854871

B?l?nescu I

1998

[A case of disseminated intravascular coagulation--a paraneoplastic manifestation of a borderline ovarian tumor].

9855613

Bachmann GA

1998

Polycystic ovary syndrome: metabolic challenges and new treatment options.

9855614

Guzick D

1998

Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology.

9855615

Taylor AE

1998

Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications.

9855616

Legro RS

1998

Polycystic ovary syndrome: current and future treatment paradigms.

9855617

Berga SL

1998

The obstetrician-gynecologist's role in the practical management of polycystic ovary syndrome.

9856217

Merkus JM

1998

[The indispensable anamnesis: in-vitro fertilization in a woman under treatment for melanoma].

9856408

Toscano V

1998

Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma.

9856409

Homburg R

1998

Polysystic ovary syndrome--loss of the apoptotic mechanism in the ovarian follicles?

9856410

Ib??ez L

1998

Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset.

9856411

Barnes RB

1998

The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies.

9856412

Carmina E

1998

Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome.

9856413

Holte J

1998

Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style?

9856414

Hall JE

1998

Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome.

9856415

Apter D

1998

How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism.

9856416

Marshall JC

1998

Estrogen-progestagen therapy in the management of the polycystic ovary syndrome.

9856417

Diamanti-Kandarakis E

1998

How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

9856418

Berga SL

1998

The feasibility of long-term treatment of polycystic ovary syndrome with GnRH-agonists.

9856419

Ehrmann DA

1998

Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options?

9856420

Cortet-Rudelli C

1998

How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome?

9856421

Castello R

1998

Highlights 1995-1998.

9856422

Moghetti P

1998

New routes in the polycystic ovary syndrome labyrinth: a way out?

9859024

Macut D

1998

Is there a role for leptin in human reproduction?

9859025

Anttila L

1998

Serum total renin levels after ovarian electrocautery in women with polycystic ovary syndrome.

9861912

Kidson W

1998

Polycystic ovary syndrome: a new direction in treatment.

9863330

Macut D

1998

[Leptin and human reproduction].

9864548

Mouroux D

1998

[Seventh congress of the National Federation of Endocrinology, Diabetes and Metabolism Regional Associations].

9864551

Pugeat M

1998

[Polycystic ovary syndrome: from physiopathology to therapy].

9864552

Deneux C

1998

[Hyperandrogenism and fertility].

9871405

Brannian JD

1998

Is the free androgen index a useful clinical marker in male patients?

9888582

Miller WL

1998

The molecular basis of isolated 17,20 lyase deficiency.

9890062

Miller WL

1998

Early steps in androgen biosynthesis: from cholesterol to DHEA.

9915618

Morrell MJ

1998

Effects of epilepsy on women's reproductive health.

9916868

Garc?a-Rudaz MC

1998

Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome.

9920059

Govind A

1999

Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families.

9920065

Gennarelli G

1999

Response of the pituitary-adrenal axis to hypoglycemic stress in women with the polycystic ovary syndrome.

9920077

Legro RS

1999

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

9920114

Nagasaka S

1999

Comment on glucose-to-insulin ratio as a measure of insulin sensitivity in women with PCOS. Polycystic ovary syndrome.

9921024

Vasiljevi? M

1998

[The role of insulin-like growth-factor binding proteins in normal and polycystic ovaries].

9922106

Legro RS

1998

Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype.

9922107

Qin KN

1998

Role of cytochrome P450c17 in polycystic ovary syndrome.

9922108

Franks S

1998

Genetics of polycystic ovary syndrome.

9922507

Sir-Petermann T

1998

[Polycystic ovary syndrome: relationship of insulin tissular sensitivity, LH secretion and ovarian morphophysiologic changes].

9922912

Taylor AE

1998

Polycystic ovary syndrome.

9924069

Morgan JF

1999

Bulimic eating patterns should be stabilised in polycystic ovarian syndrome.

9935125

Hayden CJ

1999

Induction of ovulation with the use of a starting dose of 50 units of recombinant human follicle-stimulating hormone (Puregon).

9935127

Villa P

1999

Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism.

9935135

Hovsepian DM

1999

A combined surgical and radiologic technique for creating a functional neo-endocervical canal in a case of partial congenital cervical atresia.

9987735

Murakawa H

1999

Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate.

9988404

Ajossa S

1999

Effect of chronic administration of cabergoline on uterine perfusion in women with polycystic ovary syndrome.

9988405

Carmina E

1999

Do hyperandrogenic women with normal menses have polycystic ovary syndrome?

9988406

Hasegawa I

1999

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

9989902

Syritsa A

1998

Transvaginal ultrasound-guided electrocautery of the ovaries in infertile patients with polycystic ovarian disease.

10023877

Koivunen R

1999

The prevalence of polycystic ovaries in healthy women.

10024076

Ciampelli M

1999

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome.

10037253

Unl?hizarci K

1999

The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome.

10050654

Milner CR

1999

No association between the -308 polymorphism in the tumour necrosis factor alpha (TNFalpha) promoter region and polycystic ovaries.

10065164

Homburg R

1998

Involvement of growth factors in the pathophysiology of polycystic ovary syndrome.

10065772

Filicori M

1999

The role of luteinizing hormone in folliculogenesis and ovulation induction.

10065776

Elter K

1999

Role of the mutations Trp8 => Arg and Ile15 => Thr of the human luteinizing hormone beta-subunit in women with polycystic ovary syndrome.

10065777

Diamanti-Kandarakis E

1999

Polymorphism T-->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome.

10065778

Kahsar-Miller M

1999

Dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome.

10065779

Gonzalez F

1999

Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotropic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome.

10065781

Morris RS

1999

Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome.

10065782

Penttil? TL

1999

Obesity regulates bioavailable testosterone levels in women with or without polycystic ovary syndrome.

10065783

Guido M

1999

Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome.

10065786

Pellicer A

1999

The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor.

10065863

Misajon A

1999

The mechanism of action of epidermal growth factor and transforming growth factor alpha on aromatase activity in granulosa cells from polycystic ovaries.

10074895

El Orabi H

1999

Serum leptin as an additional possible pathogenic factor in polycystic ovary syndrome.

10078583

Fridstr?m M

1999

A cost comparison of infertility treatment for clomiphene resistant polycystic ovary syndrome.

10079410

Beckers NG

1999

Retrieval, maturation, and fertilization of immature oocytes obtained from unstimulated patients with polycystic ovary syndrome.

10083900

Franks S

1998

Growth hormone and ovarian function.

10084576

Azziz R

1999

Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.

10098480

Ciampelli M

1998

Insulin in obstetrics: a main parameter in the management of pregnancy.

10098833

Luborsky JL

1999

Polycystic ovary syndrome and ovarian autoimmunity--assessment of ovarian antibodies by EIA.

10099753

Fox R

1999

Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomenorrhoea.

10099969

Carmina E

1999

The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome.

10099978

Ludwig M

1999

Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients.

10191667

Summaria V

1998

Ovarian factor infertility.

10193455

Kumar B

1997

Oligomenorrhoea, polycystic ovary syndrome and recurring miscarriage.

10199101

Johnston HF

1999

More on valproate and polycystic ovaries.

10199763

Moghetti P

1999

Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.

10199797

Huber-Buchholz MM

1999

Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.

10201083

Engmann L

1999

The pattern of changes in ovarian stromal and uterine artery blood flow velocities during in vitro fertilization treatment and its relationship with outcome of the cycle.

10202751

Sharara FI

1999

Endometrial fluid collection in women with PCOS undergoing ovarian stimulation for IVF. A report of four cases.

10202877

Mor?n C

1999

Adrenal androgen excess in hyperandrogenism: relation to age and body mass.

10202878

Minanni SL

1999

Analysis of gonadotropin pulsatility in hirsute women with normal menstrual cycles and in women with polycystic ovary syndrome.

10204203

Tan SL

1999

Clinical applications of Doppler and three-dimensional ultrasound in assisted reproductive technology.

10206219

Dolz M

1999

Polycystic ovarian syndrome: assessment with color Doppler angiography and three-dimensional ultrasonography.

10206434

Gonzalez F

1999

Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome.

10206447

Glueck CJ

1999

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.